Nucleic Acids Research, 2000, Vol. 28, No. 8 1767-1777
© 2000 Oxford University Press
Differential regulation of gene activity and chromatin structure within the human serpin gene cluster at 14q32.1 in macrophage microcell hybrids
Division of Basic Sciences, A2-025, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, PO Box 19024, Seattle, WA 98109-1024, USA
Received December 17, 1999; Revised and Accepted February 21, 2000.
| ABSTRACT |
|---|
|
|
|---|
The human gene encoding
1-antitrypsin (
1AT, gene symbol PI) is highly expressed in the liver and in cultured hepatoma cells and, to a lesser extent, in macrophages, where transcription originates from a separate upstream promoter.
1AT maps to a region of human chromosome 14q32.1 that includes a related serine protease inhibitor (serpin) gene that encodes corticosteroid-binding globulin (CBG). We recently reported the chromatin organization of this ~130 kb region, as defined by DNase I hypersensitive sites (DHSs) and matrix-attachment regions, in expressing and non-expressing cells. Furthermore, we demonstrated that transfer of human chromosome 14 from non-expressing fibroblasts to rat hepatoma cells resulted in activation of both
1AT and CBG transcription and gene activation was accompanied by long range chromatin reorganization of the entire region. In this study, we transferred human chromosome 14 from fibroblasts to mouse macrophages and documented activation of
1AT but not CBG gene expression. RTPCR experiments indicated that transcription of the human
1AT gene in the microcell hybrids initiated at the macrophage promoter. Furthermore, DHS mapping experiments revealed a distinctive chromatin configuration of the locus that resembled the structure found in human macrophage-like cell lines, with many DHSs around
1AT but few in CBG. Thus, mouse macrophage cell lines will provide a useful cell type to study the effects of targeted modifications of the human
1ATCBG locus on the regulation of cell-specific gene activity and chromatin structure. | INTRODUCTION |
|---|
|
|
|---|
The glycoprotein
1-antitrypsin (
1AT) is the most abundant serine protease inhibitor (serpin) in human plasma. Although
1AT can inhibit a wide range of serine proteases, its primary physiological target is neutrophil elastase.
1AT deficiencies are associated with increased risks of early onset pulmonary emphysema and/or juvenile liver cirrhosis.
1AT is synthesized predominantly in hepatocytes, but lower levels of expression are also found in extrahepatic tissues, particularly in blood monocytes and macrophages (1). It is believed that localized synthesis of
1AT by these cells plays a critical role in regulating the protease/protease inhibitor balance in various tissues (for reviews see 25).
1AT is a prototypical acute phase protein and its plasma concentration increases 3- to 4-fold during host responses to inflammation or tissue injury.
1AT is also expressed in intestinal cells and derived colonic adenocarcinoma cell lines (68). Studies in transgenic mice have shown that other tissues express low levels of
1AT (913), but the physiological significance of these minor expression sites is not well defined.
Human
1AT (gene symbol PI) is encoded by a unique gene located on human chromosome 14q32.1 (14,15). This region includes five other serpin genes, including
1-antichymotrypsin (AACT), corticosteroid-binding globulin (CBG), kallistatin (KAL, gene symbol PI4), protein C inhibitor (PCI) and ATR (gene symbol PIL), an antitrypsin-related sequence that may be a pseudogene (1618). We recently reported the genomic organization of this ~300 kb region and showed that the serpin gene cluster is organized into two distinct subclusters of three genes each with similar genomic organizations. The distal subcluster includes KAL, PCI and AACT, while the proximal subcluster, ~170 kb more centromeric, contains
1AT, ATR and CBG (19).
All protein-coding serpin genes in the 14q32.1 gene cluster are actively transcribed in the liver and cultured hepatoma cells. In contrast, all five genes are transcriptionally silent in most other cell types. However, a few cell types, such as macrophages and intestinal epithelial cells, express some but not all of these serpin genes. Therefore, this group of related genes provides a valuable model system to study the regulation of gene activity and chromatin structure in a large genomic region.
Chromatin structure plays an important role in regulating gene expression (for reviews see 2026). To study mechanisms that control gene activity and the chromatin structure of the serpin locus, we characterized the proximal serpin gene subcluster in detail. The
1AT, ATR and CBG genes are arranged in a head-to-tail orientation, with ~12 kb between
1AT and ATR and ~40 kb between ATR and CBG (27). The chromatin structure of this ~130 kb region, as defined by DNase I hypersensitive sites (DHSs) (28,29), is very different between expressing and non-expressing human cells. For example, HepG2 hepatoma cells, which express high levels of both
1AT and CBG, displayed 29 DHSs in the ~130 kb interval from ~25 kb upstream of
1AT to ~20 kb downstream of CBG, whereas non-expressing HeLa S3 cells or primary diploid fibroblasts have only seven sites in this region. Furthermore, we demonstrated that microcell transfer of a neo-tagged human chromosome 14 from non-expressing mouse fibroblasts to rat hepatoma cells results in activation of both
1AT and CBG gene expression to recipient cell-typical levels, and activation was accompanied by long range chromatin reorganization of the entire region such that it recapitulated the chromatin structure of expressing cells. Similarly, when chromosome 14 was transferred to rat fibroblasts,
1AT and CBG were repressed and the region displayed a chromatin configuration similar to that of non-expressing cells (30).
In human monocytes and macrophages,
1AT transcription originates from a distinct promoter located ~2 kb upstream of the well-defined liver promoter, which is also active in enterocytes (7,31). In both hepatocytes and enterocytes,
1AT gene expression requires hepatocyte nuclear factors 1
and 4 (HNF-1
and HNF-4) (3239). We recently demonstrated that the HNF-4/HNF-1
transactivation cascade also regulates CBG expression in hepatic cells and HNF-1
and HNF-4 play critical roles in the establishment of a hepatocyte-specific long range chromatin structure around both genes (40). In contrast, little is known about
1AT gene regulation in monocytes and macrophages. Transgenic mice that contain
1AT transgenes that include both promoters express human
1AT in both the liver and macrophages (9,10), but virtually nothing is known about cis-regulatory elements or trans-acting factors that regulate the activity of the macrophage promoter.
Because monocytic and macrophage cells express
1AT but not CBG, DHS analyses around these genes may provide insight into the chromatin domain organization (41) of the locus. In this study, we analyzed gene expression and chromatin structure of the proximal serpin gene subcluster in human macrophage-like cell lines. In these cell lines, expression of
1AT could be induced by incubating the cells in medium containing phorbol esters. A detailed map of DHSs in the ~130 kb region around
1AT and CBG was generated and compared to the DHS maps of expressing (hepatoma) and non-expressing (HeLa S3) cells, as well as those of activated or extinguished alleles in rat hepatoma and fibroblast microcell hybrids. We demonstrate that transfer of human chromosome 14 from non-expressing fibroblasts to mouse macrophages resulted in activation of
1AT but not CBG gene expression, and this was accompanied by long range chromatin reorganization of the region. The chromatin configuration of the locus in macrophage microcell hybrids was similar to that of human macrophage-like cell lines. Therefore, although there is no significant expression of any of the murine
1AT genes in mouse macrophages due to the absence of macrophage-specific promoters (42), these cells provide a useful background to study macrophage-specific expression and organization of the human
1AT locus.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell lines and culture conditions
The following human cell lines were obtained from the American Type Culture Collection (ATCC): the hepatocellular carcinoma cell line HepG2; the cervical carcinoma line HeLa S3; the colonic adenocarcinoma cell line Caco-2; the monocytic cell line THP-1; the histiocytic lymphoma cell line U-937; the promyelocytic leukemia cell line HL-60. The mouse macrophage cell line MH-S (derived by SV40 transformation of an adherent population of alveolar macrophages from a 7-week-old BALB/cJ mouse) and the rat fibroblast cell line Rat-2 were also obtained from ATCC. ML-1 is a human myeloblastic leukemia cell line (43). H30-1 is an HPRT-deficient derivative of HepG2 (44) and HeLa S3-neo1 is a neo-tagged, G418-resistant clone derived from HeLa S3 (unpublished data). F(14n)2, R(14n)5 and R(14n)6 are rat hepatoma and rat fibroblast microcell hybrids, respectively, that contain a single copy of human chromosome 14; they were prepared by transferring chromosome 14 from HDm-5, a mouse fibroblast (3T6) cell that contains a neo-marked human chromosome 14 derived from diploid fibroblasts (45), to Fao-1 rat hepatoma cells or Rat-2 rat fibroblasts as described (30,46). (EH4)6B and (EH4)6X, rat hepatoma variants that contain human chromosome 14 and express transfected HNF-4 expression plasmids, have been described (40). Mouse macrophage microcell hybrids were prepared similarly by transferring the neo-tagged human chromosome 14 from HDm-5 to the MH-S mouse macrophage cell line.
All cells were grown in 1:1 Hams F12:Dulbeccos modified Eagles medium (F/DV) supplemented with 10% fetal bovine serum (Gibco). F(14n)2, R(14n)5 and R(14n)6 cells were grown in medium containing 250 µg/ml G418. (EH4)6B and (EH4)6X cells were grown in medium containing 500 µg/ml G418 and 300 µg/ml hygromycin B. Mouse macrophage microcell hybrids were grown in the presence of 100 µg/ml G418. Human cell lines HL-60, ML-1, THP-1 and U-937 were induced to differentiate into macrophage-like cells by incubation in medium containing 50 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma) for 2496 h.
RNA and DNA blot hybridizations
Cytoplasmic RNAs were isolated from the cells and analyzed on 1.2% agaroseformaldehyde gels as described (30). The different probes used were:
1AT, a 567 bp BamHIDraI fragment from cosmid
ATc1 (9) containing most exon II sequences of human
1AT; exon IB of
1AT, a 0.68 kb SphIBamHI fragment from a subclone of cosmid
ATc1 (9) containing 210 bp of macrophage-specific exon IB of
1AT (31) plus intronic sequences; CBG, an ~1.5 kb EcoRI fragment containing the full-length human CBG cDNA (47); AACT, an ~1.6 kb fragment derived from phACT235 (48) containing the full-length human AACT cDNA. As loading controls, filters were rehybridized with either a rat cyclophilin cDNA probe (49) or a human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probe (50). Alternatively, the intensities of ethidium bromide stained rRNA bands were compared. Relative levels of
1AT mRNAs in the various cell lines were estimated by comparing the autoradiographic intensities of the
1AT hybridization signals to those of serially diluted HepG2 cytoplasmic RNA.
Southern hybridizations of macrophage microcell hybrids were performed as described (30) using the following probes: neo, a 1.34 kb StuISmaI fragment from cosmid vector SuperCos1 (Stratagene); cathepsin G, a 1.39 kb PstIXbaI fragment (containing exons IIIV) derived from a 3.0 kb EcoRI subclone containing the complete human cathepsin G gene (51); CBG, an ~1 kb XhoIEcoRI fragment from cosmid Ycos28 (19) located ~11 kb downstream of CBG exon 5;
1AT, the 567 bp BamHIDraI fragment from cosmid
ATc1 (9) described above; PCI, an ~1 kb SacI fragment from cosmid Ycos84 (19), located ~7 kb downstream of PCI exon V, between PCI and AACT.
RTPCR analyses
Human
1AT transcripts originating from the macrophage promoter in mouse macrophage microcell hybrids were analyzed by RTPCR using the SuperscriptTM One-StepTM RTPCR System (Life Technologies). cDNA synthesis (using 1 µg of cytoplasmic RNA per assay in a 50 µl reaction volume) was usually performed at 53°C for 30 min, followed by a 2.5 min denaturation at 94°C. The cDNA was then subjected to 35 cycles of PCR amplification (20 s denaturation at 94°C, 30 s annealing at 57°C, 90 s extension at 72°C), followed by a final extension step of 10 min at 72°C. Occasionally, more stringent conditions (RT at 55°C and annealing during the PCR up to 65°C) were used. Amplified products were visualized on 1.22% agarose gels, purified by electroelution, sequenced directly or first subcloned into pGEM-2 (Promega) and then sequenced using an ABI PRISM 377 DNA Sequencer using
1AT and/or vector-specific primers. The various human
1AT primers used in these experiments were as follows: 1A (in exon IA, overlapping an EcoRI site, underlined), 5'-GCTGCCAGGAATTCCAGGTTGGAG-3'; 1A2, (in exon IA, overlapping a StuI site, underlined), 5'-CCTCCGAGGAAGGCCTAGCTGCTG-3'; 1Bf (the 5'-end of exon IB, forward primer to amplify and/or sequence downstream sequences), 5'-GGCGGCAGTAAGTCTTCAGC-3'; 1Br (the 3'-end of exon IB, reverse primer to amplify and/or sequence upstream sequences), 5'-GGCTCAGAAACCACAGCGTC-3'; 1Cf (5'-end of exon IC), 5'-CGTTGCCCCTCTGGATCCAC-3'; 1Cr (3'-end of exon IC), 5'-TCACTGTCCCAGGTCAGTGG-3'; 2r (in exon II, reverse primer for cDNA synthesis, overlapping a BsaAI site, underlined), 5'-CTTGAGTACCCTTCTCCACGTAATCG-3'; 2r2 (in exon II, reverse primer), 5'-GGGATGTATCTGTCTTCTGGGCAGC-3'; 2r3 (in exon II, reverse primer), 5'-GGTACGGAGGAGTTCCTGGAAGCC-3'.
DNase I hypersensitive site mapping
Nuclei of the various cell lines were isolated and digested with increasing concentrations of DNase I. Purified DNA was analyzed by Southern hybridization using a variety of unique sequence probes from the
1ATATRCBG region as described (30,40). The same range of DNase I concentrations was used for each cell line.
| RESULTS |
|---|
|
|
|---|
Expression of
1AT in human macrophage-like cell linesIn humans, the gene encoding
1AT is highly expressed in liver and hepatoma cell lines. Lower levels of expression are also found in other cells, such as blood monocytes, tissue macrophages and enterocytes (1,6). Monocytes and macrophages use a macrophage-specific promoter that is located ~2 kb upstream of the well-defined liver/enterocyte promoter (31).
We first determined whether
1AT was expressed in the following macrophage-like human cell lines: the monocytic cell line THP-1, the myeloblastic leukemia cell line ML-1, the histiocytic lymphoma cell line U-937 and the promyelocytic leukemia cell line HL-60. Normally proliferating suspension cultures of these cells did not express
1AT mRNA that was detectable by northern hybridization (Fig. 1, lanes marked susp.). However, all four cell lines could be induced to differentiate into macrophage-like cells by incubation in medium con-taining TPA. Upon differentiation, the cells adhered to plastic and could be maintained for at least 4 days. Steady-state levels of
1AT mRNA in the four cell lines after incubation with TPA for 2496 h are shown in Figure 1. All four cell lines expressed
1AT after TPA treatment, although the levels and kinetics of expression varied among the different cell lines. ML-1 cells expressed the highest levels of
1AT mRNA among the four cell lines (Fig. 1) and
1AT mRNA levels in ML-1 cells cultured with TPA for 48 h approached those of HepG2 human hepatoma cells (Fig. 2, upper panel). TPA also induced
1AT mRNA expression in THP-1, U-937 and HL-60 cells, but to lower levels (Figs 1 and 2). Actively dividing Caco-2 cells, a human colonic adenocarcinoma cell line, expressed ~25-fold lower levels of
1AT mRNA than HepG2 cells; these levels were similar to those of U-937 or HL-60 cells treated with TPA for 2472 h (Fig. 2).
|
|
Using a genomic
1AT probe spanning macrophage-specific exon IB, we verified that most, if not all,
1AT transcripts detected in TPA-induced macrophage-like cells originated from the upstream macrophage promoter (Fig. 2, second panel). The low signals observed in HepG2 and Caco-2 cells with this probe were likely due to weak initiation at the macrophage promoter in these cell lines. It has been shown previously that HepG2 and Caco-2 cells can initiate transcription from the macrophage promoter under some conditions, such as during modulation by the acute phase mediator interleukin 6 (IL-6) (7). None of the human macrophage-like cell lines expressed CBG or AACT mRNAs detectable by northern hybridization, even after prolonged exposure of the RNA blots (Fig. 2, third and fourth panels, and data not shown).
Transfer of human chromosome 14 from fibroblasts to macrophage cell lines
We previously showed that microcell transfer of human chromosome 14 from fibroblasts to rat hepatoma cells resulted in activation of human
1AT and CBG gene expression, and activation was accompanied by long range chromatin reorganization of the entire ~130 kb region to a chromatin state typical of expressing cells (30,40). Mouse macrophages do not express
1AT mRNA because none of the murine
1AT genes contains a functional macrophage promoter (42). To determine whether murine macrophages would be a suitable cell type in which to study macrophage-specific expression of the human
1AT gene, we transferred human chromosome 14 to mouse macrophage MH-S cells.
A neo-marked human chromosome 14 was transferred from HDm-5, a mouse fibroblast microcell hybrid, to MH-S cells by microcell fusion. Independent microcell hybrid clones were obtained and tested for retention of an intact copy of human chromosome 14 by fluorescence in situ hybridization (FISH) and Southern marker analysis. Figure 3 shows an example of marker analysis of eight of the MH-S-derived microcell hybrid clones using probes from the neo insertion, cathepsin G (a single copy gene located at 14q11.2) and three probes from the 14q32.1 serpin gene cluster (CBG,
1AT and PCI). As negative and positive controls, the parental macrophage cell line MH-S, a rat hepatoma microcell hybrid containing human chromosome 14, F(14n)2 and the human hepatoma cell line HepG2 were used.
|
As expected, DNAs from all of the hybrid clones hybridized with a neo probe, but not all of them had an intact chromosome 14. For example, MH(14n)1 contained all three serpin genes but lacked the cathepsin G marker at 14q11.2, whereas MH(14n)7 lacked the serpin genes but contained cathepsin G. MH(14n)15 apparently contained a small human chromosome fragment that included neo but none of the other markers. However, many microcell hybrid clones, e.g. MH(14n)2, MH(14n)3, MH(14n)6, MH(14n)11 and MH(14n)12, contained an apparently intact human chromosome 14 by marker analysis (Fig. 3) and FISH (data not shown). The morphology of all of the MH-S-derived microcell hybrids was similar to that of their MH-S parent (Fig. 4).
|
Activation of human
1AT expression in mouse macrophage microcell hybridsTo determine whether the mouse macrophage microcell hybrids expressed the human
1AT gene, cytoplasmic RNAs were prepared and steady-state levels of
1AT mRNA were assayed by northern hybridization. Figure 5A shows an example of this analysis in which two halves of the same gel (left and right panels) were hybridized with
1AT and GAPDH probes.
1AT mRNA was not expressed in the parental MH-S mouse macrophage cells, in Rat-2 fibroblasts or in Rat-2-derived microcell hybrids containing human chromosome 14 [R(14n)5 and R(14n)6, Fig. 5A].
1AT mRNA was highly expressed in human HepG2 hepatoma cells and in Caco-2 colonic adenocarcinoma cells. Significantly, all of the MH-S macrophage-derived microcell hybrids that contained an intact human chromosome 14 [MH(14n)3, MH(14n)6, MH(14n)11 and MH(14n)12] expressed low but readily detectable levels of human
1AT mRNA. By comparing the autoradiographic intensities of these
1AT hybridization signals with those of control cell lines (e.g. Fig. 5A, right) or with serial dilutions of HepG2 RNA (not shown), we estimate that the MH(14n) hybrids expressed ~0.050.5% of the
1AT mRNA of HepG2 cells, where the gene is highly expressed from the hepatocyte promoter. Hybrid clones that had deleted the human serpin gene cluster (Fig. 3) did not express human
1AT mRNA [MH(14n)7 and MH(14n)15, Fig. 5A].
|
Thus, although murine
1AT genes are not expressed in mouse macrophages (42), the human
1AT locus can be activated in MH-S cells and, as shown below, transcription initiates at the human macrophage-specific promoter. Furthermore, steady-state levels of human
1AT mRNA in the MH-S microcell hybrids were generally similar to those of human macrophage-like cell lines (Figs 1 and 2). Significantly, none of the macrophage microcell hybrids expressed human CBG (Fig. 5B). These results indicate that transfer of human chromosome 14 from fibroblasts to mouse macrophages activated
1AT but not CBG gene expression in a cell-specific fashion.
Macrophage microcell hybrids use the upstream
1AT promoter
The human
1AT gene is composed of seven exons: IA, IB, IC, II, III, IV and V. In hepatocytes and enterocytes, transcription starts within exon IC. In macrophages, there are two initiation sites in exon IA (Fig. 6A) and possibly one in exon IB (7). Because
1AT mRNA is expressed at low levels in macrophages and MH-S macrophage hybrids, northern hybridization was not sufficiently sensitive to detect
1AT mRNAs using a macrophage-specific
1AT probe containing exons IA, IB and the 5'-half of IC (data not shown). Therefore, we used RTPCR to investigate whether MH-S hybrids utilized the macrophage-specific
1AT promoter.
|
Nine different primers, described in Materials and Methods, were used (Fig. 6A). Primers 1A and 2r were designed to overlap restriction sites found in exons IA and II of human
1AT (EcoRI and BsaAI, respectively) to facilitate the cloning of amplification products. Other primers in exons IA, IB, IC and II were designed and used in various combinations. Figure 6B shows the results of an experiment in which cytoplasmic RNA from the MH(14n)11 macrophage hybrid was reverse transcribed and PCR amplified using various primer pairs. Using primer pairs in exons IA/IB, IA/IC, IB/IC, IB/II and IC/II, various specific RTPCR products were obtained. For example, the 1A2/1Br and 1A/1Br primer pairs generated a 330 and a 304 bp fragment, respectively (Fig. 6B, lanes 2 and 4, respectively), that perfectly matched published IA/IB exon structures (31). Similarly, the 1Cf/2r2, 1Cf/2r3 and 1Cf/2r pairs generated the expected 213, 476 and 669 bp amplification products (Fig. 6B, lanes 12, 13 and 14, respectively). The 1A2/1Cr and 1A/1Cr primer pairs amplified two fragments that differed in size by ~200 bp (Fig. 6B, lanes 3 and 5). This was consistent with the amplification of two mRNA species, one containing exon IB and one in which IB had been removed by alternative splicing, as previously reported (7,31). However, an additional, faint band ~1520 bp shorter than the upper band in each reaction (Fig. 6B, lanes 3 and 5) was consistently observed. These products, consistently ~1520 bp shorter than the predicted size, were also observed using other primer pairs, such as 1Bf/1Cr and 1Bf/2r2 (Fig. 6B, lanes 7 and 8). They were also present, but poorly resolved, using primer pairs that yielded larger (>600 bp) amplification products (e.g. 1Bf/2r3 and1Bf/2r; Fig. 6B, lanes 9 and 10). These observations suggested that the splice donor of exon IB and/or the splice acceptor of exon IC might vary. This possibility was verified by DNA sequence analysis of the amplification products (below).
When primer pairs in exons IA and II were used (e.g. 1A/2r, 1A/2r3, 1A2/2r or 1A2/2r3), five bands were consistently amplified from macrophage RNA samples, whether from human macrophage-like cells (Fig. 6C, lane ML-1) or mouse macrophage microcell hybrids containing human chromosome 14 [Fig. 6B, lanes 1619; Fig. 6C, lanes MH(14n)6 and MH(14n)11]. These products were also produced using hepatoma RNA samples [Fig. 6C, lanes HepG2 and F(14n)2], although the upper two bands were less abundant in HepG2 RNA than in other samples. None of these amplification products were obtained using RNA from non-expressing HeLa S3 cells or in water controls (Fig. 6B, lanes 1 and 20; Fig. 6C, lanes H2O and HeLa S3). These five bands were consistently observed even when the RTPCR reactions were carried out under stringent conditions (cDNA synthesis at 55°C and annealing during PCR up to 65°C).
The nature of the five amplification products obtained using the 1A/2r primer pair (denoted IV in Fig. 7A) was investigated by nucleotide sequencing. PCR reaction products were loaded on preparative agarose gels and the bands were purified by electroelution. Only the lower, most abundant amplification product, band I, could be sequenced directly: it consisted of
1AT exon IA spliced directly to exon II (Fig. 7). This transcript utilized the expected splice donor and acceptor sites in exons IA and II and represents a previously unreported splice variant of human
1AT. The other four amplified products (bands IIV) were also purified from the gels, but they could not be sequenced directly because they were heterogeneous.
|
Bands III and V were subcloned in a plasmid vector and sequenced. As shown in Figure 7A, they represented mRNA species with the general structures IAICII and IAIBICII, respectively. However, nucleotide sequencing of a number of independent subclones from each band revealed additional complexity; there were four different molecular species in band V and two in band III. The differences between these various sequences were all found at the 3'-end of exon IB and/or the 5'-end of IC, consistent with previous RTPCR analyses (above). As shown in Figure 7B, a cryptic splice acceptor 3 bases upstream of the previously reported site 5' of exon IC created two RNA products that differed by the presence or absence of an additional CAG triplet. Similarly, a cryptic splice donor site 18 bp upstream of the 3'-end of exon IB was also used; this resulted in an exon that was 18 bp shorter at the 3'-end than that previously reported. Thus, alternative splicing at these novel sites accounted for the two molecular species that were present in band III and the four in band V, as well as the shorter products seen in previous RTPCR reactions (Fig. 6B). Other aspects of the sequences were consistent with the known structure of human
1AT genomic and cDNA (Fig. 7B).
Analysis of bands II and IV indicated that they were heteroduplexes between I and III and I and V, respectively. First, analysis of RTPCR products on denaturing gels produced only three bands, I, III and V. Second, subcloning of highly purified bands II and IV yielded only bands I and III or I and V, respectively. Third, PCR reamplification of highly purified fragments II and IV yielded only fragments I and III and I and V, respectively, when approximately 10 cycles of amplification were employed. Bands II and IV began to accumulate in these mixtures after more than 20 cycles of amplification. These data indicate that bands II and IV do not represent unique cDNA species; rather, they are merely heteroduplexes between bands I and III and I and V, respectively. Thus, macrophage microcell hybrids containing human chromosome 14 expressed three different human
1AT mRNAs with the following general structures at their 5'-ends: IAII..., IAIBII... and IAIBICII.... The IAII mRNA was a discrete molecular species, but the IAIBII and IAIBICII isoforms were heterogeneous owing to alternative splice site selection at the end of exon IB and/or the beginning of exon IC. All of these RNAs were transcribed from the human macrophage-specific promoter.
Long range chromatin reorganization accompanies gene activation in macrophage microcell hybrids
We previously showed that there are 29 DHSs in the ~130 kb
1ATATRCBG region in human hepatoma cells that express
1AT and CBG, but only seven DHSs in non-expressing cells. Furthermore, transfer of human chromosome 14 from non-expressing fibroblasts to expressing hepatoma cells resulted in activation of both
1AT and CBG gene expression and chromatin reorganization of the entire region (30), events that required HNF-1
and HNF-4 (40). To determine whether chromatin reorganization accompanied
1AT activation mediated by the macrophage-specific promoter, we mapped DHSs in human macrophage-like cell lines and macrophage microcell hybrids.
Nuclei from the human ML-1 cells grown in medium containing TPA for 48 h and from the MH(14n)6 macrophage microcell hybrid were isolated and treated with increasing concentrations of DNase I and DNA was purified, digested with appropriate restriction enzymes and analyzed by Southern hybridization as described (30,40). An example of this analysis is shown in Figure 8A, where the region at and ~5 kb upstream of the macrophage promoter of
1AT was analyzed. Both the human (ML-1) and hybrid cells [MH(14n)6] exhibited three strong DHSs at positions ~4.1 kb, 2.2 kb and ~0.15 kb. The DHSs at 4.1 and 2.2 kb were expression-associated, being present in both macrophages (Fig. 8A, left and center) and hepatic cells (30,40), but they were not found in non-expressing cells (Fig. 8A, right). The DHS at 0.15 kb was found in all cells examined (Fig. 8A; 30,40).
|
Another example of DHS mapping is shown in Figure 8B, where a region ~1014 kb downstream of CBG was analyzed. In this case, the F(14n)2 rat hepatoma microcell hybrid showed a strong site at ~+98.7 kb. This DHS was expression-associated in hepatic versus non-hepatic cells (30,40). Consistent with this, no DHS was observed at +98.7 kb in either human or hybrid macrophage cell lines [Fig. 7B, ML-1 and MH(14n)6]. These data indicate that activation of
1AT in macrophage microcell hybrids was accompanied by macrophage-specific chromatin remodeling.
DHS mapping experiments were performed throughout the
1ATCBG interval; the results are summarized in Figure 9. Human macrophage-like cells and mouse macrophage hybrids had very similar distributions of DHSs, differing by only two DHSs at ~+1.85 kb and ~+37.5 kb. This distribution of DHSs was macrophage-specific: it was distinctly different from those of both hepatic cells and non-expressing cells. Macrophage cells contained all seven constitutive DHSs mapped previously. In addition, ML-1 cells displayed 13 expression-associated DHSs, two of which (positions ~+55.1 and ~+61.5 kb) were macrophage specific, not being present in hepatic cells. Interestingly, one of these sites was within a matrix attachment region (MAR) (52), the only DHS in the entire region to be so located. Importantly, the distribution of DHSs around the
1AT gene (from ~30 to +35 kb, Fig. 9) in macrophages was similar to hepatic cells, with six of 10 expression-associated sites in common. In contrast, only two of eight expression-associated DHSs in the CBG region (+45 to +105 kb, Fig. 9) were found in macrophages. Thus, the chromatin organization of the
1AT gene region in macrophages resembles that of expressing cells, but the region around CBG is more similar to that of non-expressing cells. This raises the intriguing possibility that the chromatin configurations of the two regions might be regulated independently. Finally, the reorganization of a previously inactive human serpin allele in macrophage microcell hybrids to a macrophage-specific chromatin state provides further evidence that differentiated mammalian cells contain all of the regulatory factors required for both the establishment and maintenance of cell-specific patterns of gene activity and chromatin structure. As such, both hepatoma and macrophage microcell hybrids should be useful tools for investigating these cell-specific regulatory mechanisms.
|
| DISCUSSION |
|---|
|
|
|---|
The human serpin gene cluster at 14q32.1 provides an attractive model system to study relationships between gene activity and chromatin structure. Serpins are an ancient gene family whose various members have evolved to perform a wide variety of functions in vivo (53). As such, many serpin genes are specifically expressed in different cell types. For example, all five protein-coding serpin genes in the 14q32.1 cluster are highly expressed in liver cells, but they are transcriptionally inactive in most cell types. However,
1AT is also expressed in monocytes/macrophages and intestinal cells (1,6). Transcriptional mechanisms that regulate
1AT expression have been studied extensively and it is well established that two liver-enriched transactivators, HNF-1
and HNF-4, play major roles in activating
1AT transcription in hepatic (3238) and intestinal (39) cells. We recently demonstrated that these transactivators also regulate CBG expression in liver cells (40).
Transcription of
1AT in human monocytes/macrophages is initiated at a macrophage-specific promoter that is located ~2 kb upstream of the well-characterized liver promoter. These studies suggest that there are two, perhaps three, transcription initiation sites in macrophages, as well as alternatively spliced transcripts (7,31). However, all of the
1AT transcripts of both macrophages and liver cells encode the same
1AT protein, as the ATG translation start site is located in exon II, which is present in all the transcripts (54). As an acute phase reactant,
1AT expression is modulated by humoral agents in both hepatocytes and monocytes, particularly by IL-6 (5557).
1AT synthesis in monocytes is also modulated by bacterial lipopolysaccharide (58). Monocyte/macrophage cells appear to use the upstream promoter for both basal and modulated expression, whereas liver and intestinal cells primarily use the downstream promoter, although the macrophage promoter can be used during IL-6 modulated expression (7).
The chromatin structure of the
1ATATRCBG region, as assessed by generalized sensitivity to DNase I and by distribution of DHSs, is correlated with gene activity in hepatic versus non-hepatic cells (30,40). Furthermore, transfer of human chromosome 14 from non-expressing cells to expressing cells resulted in the activation of
1AT and CBG transcription and chromatin reorganization of the entire >100 kb region (30). Both gene activation and chromatin remodeling in hepatic cells were dependent on HNF-1
and/or HNF-4 (40).
The existence of two distinct, cell-specific promoters in the human
1AT gene suggests that human monocytes and macrophages use different cis-acting elements and trans-acting factors to regulate
1AT transcription than those that activate gene expression from the liver promoter. The specific nuclear factors that activate the human monocyte/macrophage promoter have not yet been defined, but they are clearly distinct from HNF-1
and HNF-4, which are not expressed in macrophages. In mice, the number of expressed
1AT genes varies from one to five among different Mus species (59,60). Furthermore, it was recently demonstrated that mouse macrophages do not express
1AT because none of the murine
1AT genes contains a functional macrophage promoter. This led to the conclusion that mice with mutant
1AT alleles would not be a suitable model system for human
1AT deficiency syndromes (42). However, transgenic mouse strains containing human
1AT transgenes do seem to express transgene sequences in macrophages (9,10,13), suggesting that this heterologous system might be useful for studies of macrophage-specific expression of human
1AT.
To explore this issue, we studied human
1AT expression in human macrophage-like cell lines and in macrophage microcell hybrids. The four human lines we tested could all be induced to differentiate into macrophage-like cells upon addition of TPA and
1AT mRNA expression was activated in each cell line. We mapped DHSs in the ~130 kb region around
1AT and CBG in TPA-induced ML-1 cells and found a distribution of DHSs that was distinct from that of both hepatic cells and non-expressing cells. In particular, the DHS map of the human macrophage allele revealed many expression-associated DHSs around
1AT, which was expressed, but few around CBG, which was not. Expression-associated DHSs in the
1AT promoter and 5'-flanking region were also detected in the three other human macrophage-like cell lines, demonstrating the existence of a macrophage-specific chromatin configuration in all four lines (data not shown).
To determine whether human
1AT expression could be activated in murine macrophages, we transferred human chromosome 14 from fibroblasts to MH-S cells, an SV40-transformed mouse macrophage cell line. These microcell hybrids activated expression of the human
1AT gene, but human CBG was not expressed. RTPCR analyses demonstrated that most if not all of these human transcripts initiated within the upstream macrophage promoter. Interestingly, sequencing the amplified cDNA products revealed a number of alternatively spliced
1AT transcripts. Two of these mRNA isoforms had the following structures: IAIBICIIIIIIVV and IAICIIIIIIVV (Fig. 7), as previously reported (7,31,61). However, additional transcripts were amplified from both human macrophage-like cells, hepatoma cells and microcell hybrids, but not from non-expressing cells. One predominant amplification product had the general structure IAIIIIIIVV, an mRNA species whose existence had not been described previously. We also observed mRNA isoforms that were derived from alternative splice donor/acceptor site utilization at the exon IB and/or IC boundaries; these mRNAs had not been recognized previously. The possible roles of these different
1AT mRNA isoforms in regulating mRNA stability and/or translational efficiency (7) in different cell types remain to be established.
The distributions of DHSs in the >100 kb region around
1AT and CBG in human macrophage-like cells and macrophage microcell hybrids were similar, but they were distinctly different from those of both hepatic cells and non-expressing cells. In macrophages, the region around CBG resembled the structure of non-expressing cells and extinguished microcell hybrids, with few expression-associated DHSs. However, there were many expression-associated DHSs in and around the
1AT gene (e.g. positions ~20.9, ~12.8, ~4.1, ~2.2, ~+13.4 and ~+18 kb), most of which had been mapped previously in human hepatoma cells and hepatoma microcell hybrids (30,40). These DHSs may be involved in regulatory mechanisms that are common to both cell types, such as modulation by IL-6 and other humoral agents (5557). As observed previously, the similar DHS maps of the human
1ATATRCBG locus in human cells and in mouse or rat microcell hybrids suggests that the trans-acting factors responsible for DHS formation are conserved between humans and rodents (30).
Detailed comparisons of DHS maps of the various cell lines identified expression-associated DHSs that appeared liver-specific in both the
1AT (e.g. positions ~18.9, ~5.5, ~3.4 and ~+51.9 kb, Fig. 9) and CBG gene regions (e.g. positions ~+68.9, ~+79.3 and ~+98.7 kb). Other sites found exclusively in human HepG2 hepatoma cells (positions 10, +42 and +60 kb) might be associated with regulatory regions necessary for high level
1AT expression in human hepatic cells. The seven constitutive DHSs described previously (30) were found in all cell types tested.
The ~40 kb region between ATR and CBG is an interesting intergenic interval that contains both constitutive and expression-associated DHSs. Two of these expression-associated DHSs appear to be macrophage specific. This interval also contains three MARs, each of which is composed predominantly of repetitive DNA (52). Targeted mutagenesis of this interval (62) should allow us to determine whether any of these elements play a role in regulating
1AT and/or CBG gene activity or in defining the chromatin domain structure of the locus.
The studies described in this report indicate that somatic cell hybrids provide a useful experimental system in which the expression of cell-specific genes can be altered in dramatic and reproducible ways. Together with recent studies of the
1ATATRCBG locus in hepatoma cells and fibroblasts (30,40), the data presented here demonstrate that these changes in gene activity are correlated with long range chromatin remodeling of the affected loci to recipient cell-typical states. The mapping of chromatin features in this region provides a framework for the rational design of targeting constructs and for subsequent analysis of specific mutant serpin alleles generated by homologous recombination (62).
| ACKNOWLEDGEMENTS |
|---|
We thank Mark Marsden for help with the microcell fusions, Lianjun Xu for assistance with cloning and sequencing of RTPCR products and Stephanie Namciu for critical comments on the manuscript. These studies were supported by grant GM26449 from the National Institute of General Medical Sciences. P.R. was supported by fellowships from the Swiss National Science Foundation, the Swiss League against Cancer and the Schweizerische Stiftung für Medizinisch-Biologische Stipendien.
| FOOTNOTES |
|---|
* To whom correspondence should be addressed. Tel: +1 206 667 5217; Fax: +1 206 667 6522; Email: kfournie@fhcrc.org
| REFERENCES |
|---|
|
|
|---|
-
1 Perlmutter,D.H., Cole,F.S., Kilbridge,P., Rossing,T.H. and Colten,H.R. (1985) Proc. Natl Acad. Sci. USA, 82, 795799.
2 Crystal,R.G. (1989) Trends Genet., 5, 411417.[ISI][Medline]
3 Crystal,R.G. (1990) J. Clin. Invest., 85, 13431352.
4 Povey,S. (1990) Mol. Biol. Med., 7, 161172.[ISI][Medline]
5 Perlmutter,D.H. (1998) Semin. Liver Dis., 18, 217225.[ISI][Medline]
6 Perlmutter,D.H., Daniels,J.D., Auerbach,H.S., De Schryver-Kecskemeti,K., Winter,H.S. and Alpers,D.H. (1989) J. Biol. Chem., 264, 94859490.
7 Hafeez,W., Ciliberto,G. and Perlmutter,D.H. (1992) J. Clin. Invest., 89, 12141222.
8 Molmenti,E.P., Perlmutter,D.H. and Rubin,D.C. (1993) J. Clin. Invest., 92, 20222034.
9 Kelsey,G.D., Povey,S., Bygrave,A.E. and Lovell-Badge,R.H. (1987) Genes Dev., 1, 161171.
10 Ruther,U., Tripodi,M., Cortese,R. and Wagner,E.F. (1987) Nucleic Acids Res., 15, 75197529.
11 Sifers,R.N., Carlson,J.A., Clift,S.M., DeMayo,F.J., Bullock,D.W. and Woo,S.L. (1987) Nucleic Acids Res., 15, 14591475.
12 Carlson,J.A., Rogers,B.B., Sifers,R.N., Hawkins,H.K., Finegold,M.J. and Woo,S.L. (1988) J. Clin. Invest., 82, 2636.
13 Koopman,P., Povey,S. and Lovell-Badge,R.H. (1989) Genes Dev., 3, 1625.
14 Rabin,M., Watson,M., Kidd,V., Woo,S.L., Breg,W.R. and Ruddle,F.H. (1986) Somat. Cell Mol. Genet., 12, 209214.[ISI][Medline]
15 Purrello,M., Alhadeff,B., Whittington,E., Buckton,K.E., Daniel,A., Arnaud,P., Rocchi,M., Archidiacono,N., Filippi,G. and Siniscalco,M. (1987) Cytogenet. Cell Genet., 44, 3240.[ISI][Medline]
16 Bao,J.J., Reed-Fourquet,L., Sifers,R.N., Kidd,V.J. and Woo,S.L. (1988) Genomics, 2, 165173.[Medline]
17 Hofker,M.H., Nelen,M., Klasen,E.C., Nukiwa,T., Curiel,D., Crystal,R.G. and Frants,R.R. (1988) Biochem. Biophys. Res. Commun., 155, 634642.[ISI][Medline]
18 Kelsey,G.D., Parkar,M. and Povey,S. (1988) Ann. Hum. Genet., 52, 151160.[ISI][Medline]
19 Rollini,P. and Fournier,R.E.K. (1997) Genomics, 46, 409415.[ISI][Medline]
20 Felsenfeld,G. (1992) Nature, 355, 219224.[Medline]
21 Brownell,J.E. and Allis,C.D. (1996) Curr. Opin. Genet. Dev., 6, 176184.[ISI][Medline]
22 Kingston,R.E., Bunker,C.A. and Imbalzano,A.N. (1996) Genes Dev., 10, 905920.
23 Tsukiyama,T. and Wu,C. (1997) Curr. Opin. Genet. Dev., 7, 182191.[ISI][Medline]
24 Wolffe,A.P., Wong,J. and Pruss,D. (1997) Genes Cells, 2, 291302.[Abstract]
25 Kadonaga,J.T. (1998) Cell, 92, 307313.[ISI][Medline]
26 Struhl,K. (1998) Genes Dev., 12, 599606.
27 Rollini,P. and Fournier,R.E.K. (1997) Mamm. Genome, 8, 913916.[ISI][Medline]
28 Elgin,S.C. (1988) J. Biol. Chem., 263, 1925919262.
29 Gross,D.S. and Garrard,W.T. (1988) Annu. Rev. Biochem., 57, 159197.[ISI][Medline]
30 Rollini,P. and Fournier,R.E.K. (1999) Genomics, 56, 2230.[ISI][Medline]
31 Perlino,E., Cortese,R. and Ciliberto,G. (1987) EMBO J., 6, 27672771.[ISI][Medline]
32 Courtois,G., Morgan,J.G., Campbell,L.A., Fourel,G. and Crabtree,G.R. (1987) Science, 238, 688692.
33 De Simone,V., Ciliberto,G., Hardon,E., Paonessa,G., Palla,F., Lundberg,L. and Cortese,R. (1987) EMBO J., 6, 27592766.[ISI][Medline]
34 Li,Y., Shen,R.F., Tsai,S.Y. and Woo,S.L. (1988) Mol. Cell. Biol., 8, 43624369.
35 Monaci,P., Nicosia,A. and Cortese,R. (1988) EMBO J., 7, 20752087.[ISI][Medline]
36 Costa,R.H., Grayson,D.R. and Darnell,J.E.,Jr (1989) Mol. Cell. Biol., 9, 14151425.
37 Bulla,G.A., DeSimone,V., Cortese,R. and Fournier,R.E.K. (1992) Genes Dev., 6, 316327.
38 Bulla,G.A. and Fournier,R.E.K. (1994) Mol. Cell. Biol., 14, 70867094.
39 Hu,C. and Perlmutter,D.H. (1999) Am. J. Physiol., 276, G1181G1194.
40 Rollini,P. and Fournier,R.E.K. (1999) Proc. Natl Acad. Sci. USA, 96, 1030810313.
41 Dillon,N. and Grosveld,F. (1994) Curr. Opin. Genet. Dev., 4, 260264.[Medline]
42 Tardiff,J. and Krauter,K.S. (1998) Nucleic Acids Res., 26, 37943799.
43 Herrmann,R., Han,T., Barcos,M.P., Lok,M.S. and Henderson,E.S. (1980) Cancer, 46, 13831388.[ISI][Medline]
44 Porter,M.B. and Fournier,R.E.K. (1996) Somat. Cell Mol. Genet., 22, 341348.[ISI][Medline]
45 Lugo,T.G., Handelin,B., Killary,A.M., Housman,D.E. and Fournier,R.E.K. (1987) Mol. Cell. Biol., 7, 28142820.
46 Shapero,M.H., Langston,A.A. and Fournier,R.E.K. (1994) Somat. Cell Mol. Genet., 20, 215231.[ISI][Medline]
47 Hammond,G.L., Smith,C.L., Goping,I.S., Underhill,D.A., Harley,M.J., Reventos,J., Musto,N.A., Gunsalus,G.L. and Bardin,C.W. (1987) Proc. Natl Acad. Sci. USA, 84, 51535157.
48 Chandra,T., Stackhouse,R., Kidd,V.J., Robson,K.J. and Woo,S.L. (1983) Biochemistry, 22, 50555061.[Medline]
49 Danielson,P.E., Forss-Petter,S., Brow,M.A., Calavetta,L., Douglass,J., Milner,R.J. and Sutcliffe,J.G. (1988) DNA, 7, 261267.[ISI][Medline]
50 Tso,J.Y., Sun,X.H., Kao,T.H., Reece,K.S. and Wu,R. (1985) Nucleic Acids Res., 13, 24852502.
51 Hohn,P.A., Popescu,N.C., Hanson,R.D., Salvesen,G. and Ley,T.J. (1989) J. Biol. Chem., 264, 1341213419.
52 Rollini,P., Namciu,S.J., Marsden,M.D. and Fournier,R.E.K. (1999) Nucleic Acids Res., 27, 37793791.








